The Emergence of Neisseria gonorrhoeae with Decreased Susceptibility to Azithromycin in Kansas City, Missouri, 1999 to 2000

Sexually Transmitted Diseases

Volumn 31, Issue 2, 2004, Pages 73-78

  McLean, Catherine A ^a   Wang, Susan A ^a   Hoff, Gerald L ^c   Dennis, Lesha Y ^c   Trees, David L ^b   Knapp, Joan S ^b   Markowitz, Lauri E ^a   Levine, William C ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Kansas City Health Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADULT; AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHLAMYDIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENOTYPE; GONORRHEA; HERPES; HIGH RISK POPULATION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MTRR GENE; NEISSERIA; NEISSERIA GONORRHOEAE; NONHUMAN; PHENOTYPE; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; UNITED STATES;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CASE-CONTROL STUDIES; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MISSOURI; NEISSERIA GONORRHOEAE; RISK FACTORS; RISK-TAKING;

EID: 0942279642     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.OLQ.0000109514.91508.FC     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2001. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; September 2002.
2. McCormack WM. Pelvic inflammatory disease. N Engl J Med 1994; 330:115-119.
3. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
4. Hook EW, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh P, et al., eds. Sexually Transmitted Diseases, 3rd ed. New York: McGraw-Hill; 1999:451-466.
5. Martin JE Jr, Lester A, Price EV, Schmale JD. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955-1969. J Infect Dis 1970; 122:459-461.
6. Centers for Disease Control and Prevention. Tetracycline-resistant Neisseria gonorrhoeae-Georgia, Pennsylvania, New Hampshire. MMWR Morb Mortal Wkly Rep 1985; 34:563-564.
7. Phillips I. Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet 1976; 2:656-657.
8. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272-278.
9. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR Morb Mortal Wkly Rep 2002; 51(No RR-6):30-42.
10. Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA 1990; 264:1413-1417.
11. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2001 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report - 2001. Atlanta: US Department of Health and Human Services; October 2002.
12. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990; 25(suppl A):109-114.
13. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoeae in men and women. J Antimicrob Chemother 1993; 31(suppl E):193-198.
14. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-111.
15. Physician's Desk Reference. Montvale, NJ: Medical Economics Company, Inc; 2000:2389-2396.
16. Performance standards for antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards, 2001 M100-S12; 22:53-55.
17. Mehaffey PC, Putnam SD, Barrett MS, Jones RN. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods. J Clin Microbiol 1996; 34:479-481.
18. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997; 8:299-302.
19. Tapsall JW, Shultz TR, Limnios EA, Donovan B, Lum G, Mulhall BP. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis 1998; 25:505-508.
20. Centers for Disease Control and Prevention. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in Neisseria gonorrhoeae, Missouri, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:833-837.
21. Short HB, Ploscowe VB, Weiss JA, Young FE. Rapid method for auxotyping multiple strains of Neisseria gonorrhoeae. J Clin Microbiol 1977; 6:244-248.
22. Knapp JS, Tam MR, Nowinski RC, Holmes KK, Sandstrom EG. Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I. J Infect Dis 1984; 150:44-48.
23. Trees DL, Schultz AJ, Knapp JS. Use of the neisserial lipoprotein (Lip) for subtyping Neisseria gonorrhoeae. J Clin Microbiol 2000; 38:2914-2916.
24. Johnson SR, Sandul AL, Parekh M, Wang S, Knapp JS, Trees DL. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. Int J Antimicrob Agents 2003; 21:414-419.
25. Siegel MS, Thornsberry C, Biddle JW, O'Mara PR, Perine PL, Wiesner PJ. Penicillinase-producing Neisseria gonorrhoeae: results of surveillance in the United States. J Infect Dis 1978; 137:170-175.
26. Hook EW, Brady WE, Reichart CA, Upchurch DM, Sherman LA, Wasserheit JN. Determinants of emergence of antibiotic-resistant Neisseria gonorrhoeae. J Infect Dis 1989; 159:900-907.
27. McCaig LF, Burt CW. Trends in the use of azithromycin/clarithromycin and the quinolones for selected infectious diseases in ambulatory care settings in the US, 1993/94-1999/2000. In: Program and abstracts of the International Conference on Emerging Infectious Diseases; Atlanta, GA; 2002.
28. Zarantonelli L, Borthagaray G, Lee E, Shafer WM. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother 1999; 43:2468-2472.
29. Dillon JR, Rubabaza JA, Benzaken AS, et al. Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998. Sex Transm Dis 2001; 28:521-526.
30. Dillon JR, Li H, Sealy J, Ruben M, The Carribean GASP Network, Prabhakar P. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from three Caribbean countries: Trinidad, Guyana, and St. Vincent. Sex Transm Dis 2001; 28:508-514.
31. Centers for Disease Control and Prevention. Increases in Fluoroquinolene-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortality Wkly Rep 2002; 51:1041-1049.
32. Fox KK, Knapp JS, Holmes KK, et al. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones. J Infect Dis 1997; 175:1396-1403.
33. Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime, Hawaii, 2001. Clin Infect Dis 2003; 37:849-852.